# South Korea Neurodegenerative Disease Market

> South Korea Neurodegenerative Disease Market Research Report: Size, Share, Trend Analysis By Disease Type (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Huntington's Disease), By Diagnosis Method (Neurological Examination, Imaging Techniques, Cerebrospinal Fluid Analysis, Electrophysiological Tests), By Treatment Type (Medication, Therapy, Rehabilitation, Surgical Interventions) and By Route of Administration (Oral, Injectable, Intravenous, Transdermal) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.6%
- **2024:** $ 2,048.16 Million
- **2025:** $ 2,203.82 Million
- **2035:** $ 4,585.5 Million
- **Key Players:** Biogen (US), Eli Lilly (US), Roche (CH), Novartis (CH), AstraZeneca (GB), Merck & Co (US), Amgen (US), Sanofi (FR), AbbVie (US)

**Report ID:** MRFR/LS/50851-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/south-korea-neurodegenerative-disease-market-52610

---

## Market Summary

## **South Korea Neurodegenerative Disease Market Overview**

As per MRFR analysis, the South Korea Neurodegenerative Disease Market Size was estimated at 442 (USD Million) in 2023. The South Korea Neurodegenerative Disease Market Industry is expected to grow from 466.6(USD Million) in 2024 to 1,200 (USD Million) by 2035. The South Korea Neurodegenerative Disease Market CAGR (growth rate) is expected to be around 8.967% during the forecast period (2025 - 2035).

**Key South Korea Neurodegenerative Disease Market Trends Highlighted**

The South Korea Neurodegenerative Disease Market is witnessing significant market trends driven by an aging population and increasing prevalence of diseases such as Alzheimer's and Parkinson's. The government of South Korea has initiated various healthcare programs aimed at early diagnosis and innovative treatment methods for neurodegenerative diseases. This effort has accelerated research and development in the biotech sector, as there is a strong focus on creating new therapies and incorporating advanced technologies like artificial intelligence into treatment protocols.

Opportunities exist for companies to explore cutting-edge solutions such as gene therapy and stem cell treatments, motivating them to expand their R&D capabilities.In recent times, there has been a marked increase in collaborative efforts between South Korean universities and research institutions, fostering innovation within the neurodegenerative disease sector. These collaborations are crucial as they optimize resource sharing and accelerate the drug development process. Furthermore, rising public awareness about mental health and neurodegenerative disease is prompting greater investment from both public and private sectors into specialized healthcare facilities and support services.

This cultural shift is opening up avenues for startups focusing on digital health platforms that support patients and caregivers.The South Korean government is also supporting initiatives to improve the quality of life for elderly patients suffering from neurodegenerative conditions. Programs that encourage home care services and telehealth solutions are becoming increasingly popular, as they allow for more accessible and personalized care. Overall, the landscape of the South Korea Neurodegenerative Disease Market is evolving rapidly, presenting numerous opportunities for innovation and effective treatment strategies to better address the challenges posed by these debilitating diseases.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**South Korea Neurodegenerative Disease Market Drivers**

**Increasing Aging Population**

South Korea's elderly population is rapidly increasing, which is driving the expansion of the South Korea Neurodegenerative Disease Market Industry. According to Alzheimer's Disease International, the number of persons aged 65 and older in South Korea is predicted to reach 14.8 million by 2050, up from around 8.9 million in 2020. This demographic change causes an increase in the prevalence of neurological disorders, including Alzheimer's and Parkinson's.

With official data from the Korean Statistical Information Service indicating that the elderly population will reach 40% by 2060, demand for neurodegenerative treatments and supportive services is expected to rise, driving market growth and prompting investments from key stakeholders such as the Korean Institute of Health and Social Affairs in research initiatives and elderly care services.

**Advancements in Research and Development**

The South Korea Neurodegenerative Disease Market Industry is witnessing significant advancements in Research and Development (R&D) activities, enhancing treatment modalities for neurodegenerative diseases. The South Korean government has increased funding for innovative healthcare initiatives, with the Ministry of Health and Welfare reporting an allocation of 600 billion KRW for R&D in the healthcare sector in 2021.

As a result, many biotechnology companies, such as Samsung Biologics and Celltrion, are actively engaging in the development of new therapies and medicines targeting neurodegenerative diseases.This trend is expected to fuel the market's growth, given that emerging treatments can significantly improve patient outcomes and address critical unmet needs in the community.

**Growing Awareness and Diagnosis**

There is an increasing awareness and improved diagnostic methods for neurodegenerative diseases in South Korea, which plays a pivotal role in the expansion of the South Korea Neurodegenerative Disease Market Industry. Campaigns by the Korean Alzheimer’s Association have significantly raised public awareness, leading to better recognition of symptoms and earlier diagnosis.

Moreover, a report from the Korea Institute for Health and Social Affairs highlights that the number of diagnosed Alzheimer's cases has risen by 15% over the past five years.This spike in awareness is critical, as earlier intervention can lead to better management of conditions, prompting healthcare providers to invest more in diagnostic tools and therapeutic solutions to meet the rising demand.

**South Korea Neurodegenerative Disease Market Segment Insights**

**Neurodegenerative Disease Market Disease Type Insights**

The South Korea Neurodegenerative Disease Market, within the context of Disease Type, encompasses various critical ailments, each with unique characteristics and demands. Among these, Alzheimer’s Disease stands out as a significant contributor to market growth, driven by an aging population and increasing awareness surrounding cognitive health. The prevalence of Alzheimer’s in South Korea has led to sophisticated Healthcare strategies aimed at early diagnosis and treatment, prompting innovations in Research and Development throughout the industry. Similarly, Parkinson’s Disease represents another vital area within this segment, characterized by its profound impact on motor functions, calling for robust therapeutic approaches.

The South Korean government has recently emphasized the importance of personalized medicine to address the specific needs of patients suffering from this debilitating condition.Multiple Sclerosis, while less prevalent than Alzheimer’s and Parkinson’s, still commands attention within healthcare frameworks in South Korea due to its challenging nature and the importance of holistic patient management. The increasing number of cases is prompting collaborations among academic institutions and biotech firms to develop targeted therapies. Furthermore, Amyotrophic Lateral Sclerosis stands as one of the most critical focal points in neurodegenerative research, with significant implications for healthcare systems, as it requires advanced caregiving solutions.

The community response has led to support networks and awareness campaigns, significantly enhancing public understanding and engagement with this severe illness. Huntington's Disease, though rarer, contributes to the landscape by highlighting the need for advances in genetic research and therapy development. Moreover, the South Korea Neurodegenerative Disease Market segmentation shows that caregivers, families, and patients emphasize quality of life and access to groundbreaking treatments, influencing the trajectory of both policy and resource allocation. This highlights the inherent challenges and opportunities within the market, driven by the need to improve diagnostic methods and therapeutic interventions across the various disease types.

Collectively, these disorders represent crucial areas of focus for the South Korean healthcare system, tailored to manage the complexities associated with neurodegenerative diseases effectively. As the nation develops its policies and resources, the continuous evolution of treatment strategies remains a key component of addressing the implications of these diseases on society.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Neurodegenerative Disease Market Diagnosis Method Insights**

The Diagnosis Method segment within the South Korea Neurodegenerative Disease Market encompasses critical techniques that play an essential role in the accurate identification of various neurodegenerative conditions. Neurological Examination offers vital preliminary assessments, enabling healthcare professionals to evaluate patients efficiently and formulate further diagnostic pathways. Imaging Techniques, such as MRI and CT scans, provide sophisticated visualization of brain structures, aiding in the detection of encephalopathies and other abnormalities. Cerebrospinal Fluid Analysis is crucial in diagnosing conditions like Alzheimer's and multiple sclerosis, as it allows for the assessment of biomarkers indicative of these diseases.

Meanwhile, Electrophysiological Tests, including EEGs, are significant for diagnosing movement disorders and assessing neuronal activity. Overall, these methods collectively enhance diagnosis accuracy, ultimately leading to improved treatment outcomes. The integration of advanced diagnostic technologies is projected to drive innovation in the field, addressing the growing demand for effective neurodegenerative disease management in South Korea.As the population ages, the reliance on these diagnostic methods will likely increase, highlighting their importance in the evolving landscape of healthcare.

**Neurodegenerative Disease Market Treatment Type Insights**

The South Korea Neurodegenerative Disease Market is expanding significantly, with a marked focus on the Treatment Type segment that encompasses various approaches critical for managing these complex diseases. Medication is a prominent strategy, aiming to alleviate symptoms and slow disease progression, particularly in conditions like Alzheimer's and Parkinson's. Meanwhile, Therapy addresses cognitive and physical aspects affected by neurodegenerative disorders, offering essential rehabilitation and psychological support crucial for enhancing patients' quality of life.Rehabilitation plays an important role in helping individuals recover or maintain their functional abilities, emphasizing personalized procedures tailored to specific needs.

Surgical Interventions are also noted for their potential in treating advanced stages of certain neurodegenerative diseases, providing an essential option when other treatments have ceased to be effective. The growth in the South Korea Neurodegenerative Disease Market revenue is driven by an aging population and increasing awareness regarding these conditions.

Furthermore, the integration of advanced technologies into treatment methodologies presents opportunities for innovative therapeutic options, as healthcare professionals seek to improve patient outcomes through more effective management techniques.The trends observed in this sector reflect a commitment to enhancing the standard of care and addressing the challenges posed by neurodegenerative diseases within South Korea's healthcare system.

**Neurodegenerative Disease Market Route of Administration Insights**

The Route of Administration segment within the South Korea Neurodegenerative Disease Market showcases a diverse landscape that is crucial for effective treatment delivery. Oral administration remains popular due to its ease of use and patient compliance, making it a predominant choice among healthcare providers. Injectable routes are also significant, particularly for medications that require rapid absorption or specific dosage control, catering to patients who need precise treatment for neurodegenerative disorders.

Intravenous methods are essential in acute care settings, allowing for immediate therapeutic effects, which can be life-saving in advanced cases.Meanwhile, Transdermal administration is gaining traction for its convenience and reduced gastrointestinal side effects, offering patients a non-invasive alternative for symptom management. With the South Korean population aging and the increasing prevalence of neurodegenerative diseases like Alzheimer’s and Parkinson’s, the variety of administration routes available plays a vital role in optimizing treatment efficacy and patient adherence.

Furthermore, the ongoing innovation in drug delivery systems continues to enhance the performance of these administration routes, ultimately contributing to the overall development of the market.

**South Korea Neurodegenerative Disease Market Key Players and Competitive Insights**

The South Korea Neurodegenerative Disease Market is a dynamic and rapidly evolving sector that focuses on an array of conditions affecting the nervous system, such as Alzheimer's, Parkinson's disease, and multiple sclerosis. This market is driven by increasing prevalence rates of neurodegenerative diseases, elevating the demand for more innovative therapeutic solutions. Moreover, the strong research and development capabilities of local firms, along with a well-established healthcare infrastructure, have positioned South Korea as a competitive player in the Asia-Pacific neurodegenerative therapeutic landscape.

The market is characterized by various strategic collaborations, partnerships between research institutions and pharmaceutical companies, as well as the growing trend of personalized medicine. These competitive insights indicate an industry ripe for both challenges and opportunities, with the potential for novel treatments to emerge amid rigorous regulatory frameworks and evolving patient needs.Celltrion has established itself as a prominent player in the South Korea Neurodegenerative Disease Market by leveraging its expertise in biotechnology and biosimilars.

The company’s presence in this sector is built upon its strong commitment to research and development, resulting in the introduction of innovative therapeutic solutions aimed at alleviating symptoms associated with neurodegenerative conditions. The robust regulatory compliance and approval processes that Celltrion adheres to have bolstered its credibility in the market. Additionally, the company has developed strategic alliances within the healthcare ecosystem, further enhancing its competitive edge.

These strengths enable Celltrion to effectively address both local and global market demands while maintaining a significant focus on advancing treatment options for patients suffering from neurodegenerative diseases in South Korea.LG Chem holds a noteworthy position in the South Korea Neurodegenerative Disease Market, distinguished by its comprehensive portfolio of products focusing on innovation and therapeutic efficacy. The company has made significant strides in research and development, culminating in key products aimed specifically at neurodegenerative diseases.

LG Chem benefits from a strong market presence, underpinned by its extensive distribution network and collaborations with leading research institutions and healthcare providers in South Korea. The company has also engaged in strategic mergers and acquisitions, which have expanded its capabilities and strengthened its position within the neurodegenerative sector. By emphasizing high-quality solutions and being committed to continuous advancement in treatment methodologies, LG Chem remains a formidable competitor in addressing the growing challenges posed by neurodegenerative diseases in the region.

**Key Companies in the South Korea Neurodegenerative Disease Market Include**

- Celltrion
- LG Chem
- Hanmi Pharmaceutical
- Daewoong Pharmaceutical
- Green Cross
- Korea United Pharm
- Samsung Biologics
- Korea Research Institute of Bioscience and Biotechnology
- Novartis
- Biogen
- Roche
- Medytox
- Korea Institute of Science and Technology
- Pharmaron Beijing
- SK Biopharmaceuticals

**South Korea Neurodegenerative Disease Market Industry Developments**

The South Korea Neurodegenerative Disease Market has witnessed significant developments recently. In October 2023, LG Chem announced progress in its Research and Development pipeline for neurodegenerative treatments, focusing on Alzheimer’s disease therapies. Meanwhile, SK Biopharmaceuticals has been recognized for its breakthrough drug for epilepsy, reflecting the growing momentum in the biopharmaceutical sector related to neurodegenerative disorders. Hanmi Pharmaceutical and Daewoong Pharmaceutical are also actively collaborating to explore innovative treatments aimed at neurodegeneration, showcasing a trend towards joint ventures in product development.

In terms of market valuation, major players like Samsung Biologics reported increased revenue due to heightened demand for biologics, particularly in treatments for neurodegenerative diseases. The market's growth has also been bolstered by funding from the Korean government, which is directing resources into biotechnology startups focused on neurodegenerative research. In terms of mergers and acquisitions, there have been speculations surrounding Green Cross and future collaborative efforts in developing neurodegenerative disease therapies, though no formal announcements have been made as of now. The South Korean neurodegenerative disease market continues to evolve, driven by innovation and strategic partnerships.

**South Korea Neurodegenerative Disease Market Segmentation Insights**

**Neurodegenerative Disease Market Disease Type****Outlook**

- Alzheimer's Disease
- Parkinson's Disease
- Multiple Sclerosis
- Amyotrophic Lateral Sclerosis
- Huntington's Disease

**Neurodegenerative Disease Market Diagnosis Method****Outlook**

- Neurological Examination
- Imaging Techniques
- Cerebrospinal Fluid Analysis
- Electrophysiological Tests

**Neurodegenerative Disease Market Treatment Type****Outlook**

- Medication
- Therapy
- Rehabilitation
- Surgical Interventions

**Neurodegenerative Disease Market Route of Administration****Outlook**

- Oral
- Injectable
- Intravenous
- Transdermal

## Market Drivers

### Emerging Therapeutic Approaches

The neurodegenerative disease market is witnessing a surge in emerging therapeutic approaches, including gene therapy and stem cell research. These innovative treatments hold the potential to alter the course of diseases that were previously deemed untreatable. In South Korea, several clinical trials are underway, exploring the efficacy of these novel therapies. The market is likely to experience significant growth as these therapies progress through clinical stages and receive regulatory approval. The promise of new treatment modalities not only excites the medical community but also offers hope to patients and their families, thereby driving demand in the neurodegenerative disease market.

### Growing Awareness and Education

There is a growing awareness of neurodegenerative diseases among the South Korean population, which is driving demand for better treatment options. Educational campaigns aimed at both healthcare professionals and the public are crucial in promoting understanding of these conditions. As awareness increases, patients are more likely to seek medical advice and treatment, thereby expanding the market. The neurodegenerative disease market must capitalize on this trend by providing accessible information and resources to patients and caregivers. This heightened awareness could lead to earlier diagnosis and intervention, ultimately improving patient outcomes and market growth.

### Government Initiatives and Funding

Government initiatives aimed at addressing neurodegenerative diseases are pivotal for the market's expansion. In South Korea, the government has allocated substantial funding for research and development in this field, with investments reaching approximately $200 million annually. These initiatives focus on enhancing public awareness, improving healthcare infrastructure, and supporting clinical trials for new therapies. The neurodegenerative disease market stands to gain from these efforts, as increased funding can lead to breakthroughs in treatment options and better patient care. Furthermore, collaboration with academic institutions and private sectors is likely to foster innovation and accelerate the development of effective therapies.

### Advancements in Diagnostic Technologies

Technological advancements in diagnostic tools are transforming the neurodegenerative disease market. Innovations such as neuroimaging techniques and biomarker identification are enabling earlier and more accurate diagnoses. For instance, the introduction of PET scans and MRI technology has improved the detection of neurodegenerative conditions, allowing for timely intervention. The market is likely to benefit from these advancements, as they not only enhance patient outcomes but also reduce long-term healthcare costs. As diagnostic capabilities improve, the demand for targeted therapies and personalized treatment plans is expected to rise, further stimulating market growth in South Korea.

### Aging Population and Increased Incidence

The aging population in South Korea is a critical driver for the neurodegenerative disease market. As life expectancy rises, the prevalence of neurodegenerative diseases such as Alzheimer's and Parkinson's is expected to increase significantly. Current estimates suggest that by 2030, approximately 1.5 million individuals in South Korea will be living with dementia, which represents a substantial rise from previous years. This demographic shift necessitates enhanced healthcare services and innovative treatment options, thereby propelling market growth. The neurodegenerative disease market must adapt to these changing demographics by focusing on early diagnosis and effective management strategies to cater to the growing patient population.

## Future Outlook

The [Neurodegenerative Disease Market](https://www.marketresearchfuture.com/reports/neurodegenerative-disease-market-19218) in South Korea is projected to grow at a 7.6% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in treatment options.

**New opportunities:**

- Development of personalized medicine solutions for neurodegenerative disorders. Expansion of telehealth services for remote patient monitoring and consultations. Investment in AI-driven drug discovery platforms targeting neurodegenerative diseases.

By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic investments.

## Segment Insights

### By Disease Type: Alzheimer's Disease (Largest) vs. Parkinson's Disease (Fastest-Growing)

In the South Korea neurodegenerative disease market, Alzheimer's Disease represents the largest share, reflecting the significant burden it places on the population. This segment is followed closely by Parkinson's Disease, which, despite its lower market share, is witnessing remarkable growth due to increasing incidence rates and heightened awareness.

Growth trends in this segment are largely driven by advancements in therapeutic options and increased investment in research and development. The rising aging population in South Korea contributes to the escalation in both diseases, mandating a robust response from healthcare systems. Parkinson's Disease, in particular, benefits from innovative treatment strategies, garnering it recognition as the fastest-growing segment in this market.

Alzheimer's Disease (Dominant) vs. Parkinson's Disease (Emerging)

Alzheimer's Disease stands out as the dominant force in the South Korea neurodegenerative disease market, primarily due to its entrenched presence and the extensive support networks established for affected individuals and their families. Therapeutic approaches for Alzheimer's have been evolving, giving rise to a more tailored management strategy. Conversely, Parkinson's Disease is emerging rapidly, fueled by a younger demographic diagnosed with the condition and innovative treatment modalities. This segment experiences a surge in clinical trials, indicating a promising future pipeline that attracts both regulatory and private sector interest. As both conditions receive significant attention, the gap between their market positions continues to narrow.

### By Diagnosis Method: Neurological Examination (Largest) vs. Imaging Techniques (Fastest-Growing)

In the South Korea neurodegenerative disease market, the diagnosis methods are characterized by significant distribution among four primary segments: Neurological Examination, Imaging Techniques, Cerebrospinal Fluid Analysis, and Electrophysiological Tests. Neurological Examination currently holds the largest market share, being the most common and trusted method in diagnosing various neurodegenerative diseases. Imaging Techniques have also gained traction, attributed to advancements in technology and better patient outcomes. 

The growth trends in these methods are particularly influenced by technological advancements and increased awareness about neurodegenerative diseases among healthcare professionals and the public. Imaging Techniques are recognized as the fastest-growing method, driven by innovations in imaging technology and the rising prevalence of neurodegenerative disorders. As patients demand more efficient diagnostic tools, healthcare providers are increasingly adopting these innovative techniques to improve diagnostic accuracy and patient management.

Neurological Examination (Dominant) vs. Imaging Techniques (Emerging)

The dominant segment, Neurological Examination, stands out for its clinical effectiveness and established history in the diagnostic process. It encompasses patient history, mental status examination, and a physical examination, making it the preferred choice among clinicians. On the other hand, Imaging Techniques represent the emerging segment in this context, leveraging advanced technologies like MRI and CT scans to enhance diagnostic capabilities. These methods support the identification of neurodegenerative diseases at earlier stages, which is crucial for timely intervention. As technology continues to evolve, the demand for Imaging Techniques is expected to rise, thus influencing their market position positively.

### By Treatment Type: Medication (Largest) vs. Therapy (Fastest-Growing)

In the South Korea neurodegenerative disease market, the treatment type segment is predominantly led by medication, which constitutes a significant share owing to its established use in managing symptoms. Therapy also holds a noteworthy share as it complements medication, providing holistic care approaches for patients seeking relief from neurodegenerative conditions. Rehabilitation and surgical interventions follow but represent smaller portions of the market share, indicating a focus on non-invasive treatment modalities.

The growth trends in this segment are heavily influenced by an aging population and increasing neurological disorders, driving a robust demand for effective treatment options. Innovation and advancements in medication are also propelling growth, while therapy, increasingly recognized for its benefits, is rapidly gaining traction. This dual momentum reflects a shift towards integrative approaches in managing neurodegenerative diseases, with both medication and therapy playing pivotal roles in patient care.

Medication (Dominant) vs. Therapy (Emerging)

Medication remains the dominant force in the treatment landscape for neurodegenerative diseases due to its long-standing efficacy and continuous innovations. Various pharmacological options cater to multiple conditions, making it essential for patients seeking immediate relief. Therapy, while emerging, shows considerable promise, appealing to those who prefer comprehensive treatments encompassing physical, occupational, and cognitive methodologies. This segment’s growth is also fueled by raising awareness about alternative therapies and the growing acknowledgment of their role in enhancing patient quality of life. As both treatment avenues evolve, they are likely to coexist, presenting a well-rounded framework for managing neurodegenerative diseases.

### By Route of Administration: Oral (Largest) vs. Injectable (Fastest-Growing)

The market for routes of administration in the South Korea neurodegenerative disease market reveals various dynamics among segment values. Oral administration is currently the largest segment, widely preferred for its ease of use and patient compliance. In contrast, injectable routes, while smaller in market share, are gaining momentum due to advancements in formulation technologies that improve patient experiences. This segment distribution reflects preferences that are evolving as patients and providers seek efficacy and convenience in treatment options.

Growth trends within the routes of administration are driven by innovations in drug formulations and delivery mechanisms. The injectable segment is recognized as the fastest-growing, propelled by the introduction of novel biologics and specialty drugs targeting neurodegenerative conditions. Furthermore, increased investments in research and development are fostering the emergence of transdermal patches, which offer an alternative for patients hesitant about injections, thereby contributing to the diversification of the segment’s growth strategies.

Oral (Dominant) vs. Injectable (Emerging)

Oral administration stands out as the dominant route in the South Korea neurodegenerative disease market, appreciated for its accessibility and adherence rates among patients. This segment is characterized by a wide range of formulations, including tablets and capsules, catering to diverse patient needs. On the other hand, injectable products are emerging as a crucial alternative, especially for advanced therapies that require precise dosing and rapid onset of action. The rise of this segment is spurred by the growing acceptance of biologics and monoclonal antibodies, which often necessitate parenteral delivery methods. As the market evolves, both oral and injectable routes will continue to play significant roles in addressing the complexities of neurodegenerative treatment paradigms.

## Competitive Benchmarking

The [neurodegenerative disease market](https://www.marketresearchfuture.com/reports/neurodegenerative-disease-market-19218) in South Korea is characterized by a dynamic competitive landscape, driven by increasing prevalence rates and a growing aging population. Key players such as Biogen (US), Eli Lilly (US), and Roche (CH) are strategically positioned to leverage innovation and partnerships to enhance their market presence. Biogen (US) focuses on developing novel therapies for Alzheimer's disease, while Eli Lilly (US) emphasizes its pipeline of treatments for various neurodegenerative conditions. Roche (CH) is investing heavily in personalized medicine, which appears to be a significant trend shaping the competitive environment. Collectively, these strategies indicate a shift towards more targeted and effective treatment options, thereby intensifying competition among these major players.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure is moderately fragmented, with several players vying for market share. However, the influence of key players is substantial, as they often set the pace for innovation and market trends. This competitive structure suggests that while there is room for smaller companies, the dominance of established firms is likely to shape the market's future trajectory.

In October  Biogen (US) announced a collaboration with a leading South Korean biotech firm to develop a new treatment for Alzheimer's disease. This partnership is strategically significant as it not only enhances Biogen's research capabilities but also allows for localized clinical trials, potentially accelerating the development process. Such collaborations may also facilitate better market penetration in South Korea, where the demand for effective treatments is rapidly increasing.

In September  Eli Lilly (US) launched a new digital health platform aimed at improving patient engagement and adherence to treatment regimens for neurodegenerative diseases. This initiative underscores the company's commitment to integrating technology into healthcare, which is becoming increasingly vital in managing chronic conditions. By leveraging digital tools, Eli Lilly (US) may enhance patient outcomes and solidify its competitive edge in the market.

In August  Roche (CH) unveiled a new biomarker discovery initiative focused on early diagnosis of neurodegenerative diseases. This strategic move is crucial as early detection can significantly improve treatment outcomes. Roche's investment in biomarker research indicates a forward-thinking approach that could redefine treatment paradigms in the neurodegenerative space, positioning the company as a leader in innovative diagnostics.

As of November  current competitive trends in the neurodegenerative disease market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) in drug development. Strategic alliances are increasingly shaping the landscape, allowing companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift suggests that companies that prioritize research and development, alongside strategic partnerships, will be better positioned to thrive in this rapidly changing market.

## Recent News & Developments

The South Korea Neurodegenerative Disease Market has witnessed significant developments recently. In October 2023, LG Chem announced progress in its Research and Development pipeline for neurodegenerative treatments, focusing on Alzheimer’s disease therapies. Meanwhile, SK Biopharmaceuticals has been recognized for its breakthrough drug for epilepsy, reflecting the growing momentum in the biopharmaceutical sector related to neurodegenerative disorders. Hanmi Pharmaceutical and Daewoong Pharmaceutical are also actively collaborating to explore innovative treatments aimed at neurodegeneration, showcasing a trend towards joint ventures in product development.

In terms of market valuation, major players like Samsung Biologics reported increased revenue due to heightened demand for biologics, particularly in treatments for neurodegenerative diseases. The market's growth has also been bolstered by funding from the Korean government, which is directing resources into biotechnology startups focused on neurodegenerative research. In terms of mergers and acquisitions, there have been speculations surrounding Green Cross and future collaborative efforts in developing neurodegenerative disease therapies, though no formal announcements have been made as of now. The South Korean neurodegenerative disease market continues to evolve, driven by innovation and strategic partnerships.

## Report Scope

| MARKET SIZE 2024 | 2048.16(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 2203.82(USD Million) |
| MARKET SIZE 2035 | 4585.5(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.6% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Biogen (US), Eli Lilly (US), Roche (CH), Novartis (CH), AstraZeneca (GB), Merck & Co (US), Amgen (US), Sanofi (FR), AbbVie (US) |
| Segments Covered | Disease Type, Diagnosis Method, Treatment Type, Route of Administration |
| Key Market Opportunities | Advancements in biomarker discovery enhance early diagnosis and treatment options in the neurodegenerative disease market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the neurodegenerative disease market. |
| Countries Covered | South Korea |

## Frequently Asked Questions

**Q: What was the overall market valuation for the neurodegenerative disease market in 2024?**
A: The overall market valuation was $2048.16 Million in 2024.

**Q: What is the projected market valuation for the neurodegenerative disease market by 2035?**
A: The projected market valuation for 2035 is $4585.5 Million.

**Q: What is the expected CAGR for the neurodegenerative disease market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during the forecast period 2025 - 2035 is 7.6%.

**Q: Which companies are considered key players in the neurodegenerative disease market?**
A: Key players include Biogen, Eli Lilly, Roche, Novartis, AstraZeneca, Merck & Co, Amgen, Sanofi, and AbbVie.

**Q: What are the market segments based on disease type in the neurodegenerative disease market?**
A: Market segments include Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Huntington's Disease.

**Q: What was the valuation range for Alzheimer's Disease in 2024?**
A: The valuation range for Alzheimer's Disease was $400.0 Million to $900.0 Million in 2024.

**Q: What is the projected valuation range for imaging techniques in the neurodegenerative disease market?**
A: The projected valuation range for imaging techniques is $800.0 Million to $1800.0 Million.

**Q: What treatment types are included in the neurodegenerative disease market?**
A: Treatment types include Medication, Therapy, Rehabilitation, and Surgical Interventions.

**Q: What is the valuation range for injectable treatments in the neurodegenerative disease market?**
A: The valuation range for injectable treatments is $800.0 Million to $1800.0 Million.

**Q: What is the significance of the neurodegenerative disease market in South Korea?**
A: The neurodegenerative disease market in South Korea is poised for growth, with a projected valuation increase to $4585.5 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-neurodegenerative-disease-market-52610*